
Chinese innovative drug company established on 10 March 2021 in Zhangjiang Science City, Shanghai, occupying about 2,500 square metres and co-founded by two experienced industry figures, Hu Shaojing and Cai Mingqing, the former having previously founded two listed pharmaceutical companies. Develops highly selective small molecule drugs, highly selective therapeutic antibodies and next generation antibody drug conjugates, with dual target drug development as its stated direction. Its pipeline focuses on oncology, cancer immunology and autoimmune disease, concentrating in the near term on clinically validated targets, and it raised about two hundred million yuan in its Series A round.
Voir le profil de l'entreprise
Laissez votre note